SCHEMBL29696396

SCHEMBL29696396

Cc1nc2nc(-n3ccnc3)nc(C(=O)NC3CCC(F)(F)CC3)c2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CD38 P28907 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22932812 1.00 CD38 (1.00) CD38
SCHEMBL32688207 0.86 CD38 (1.00) CD38
SCHEMBL22933181 0.86 CD38 (1.00) CD38
SCHEMBL22947545 0.84 CD38 (0.73) CD38
SCHEMBL31484524 0.84 CD38 (0.73) CD38
SCHEMBL22947524 0.80 CD38 (0.79) CD38
SCHEMBL29696371 0.80 CD38 (0.79) CD38
SCHEMBL22932811 0.75 CD38 (0.81) CD38
SCHEMBL22933178 0.75 CD38 (0.72) CD38
SCHEMBL29696451 0.75 CD38 (0.72) CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431323-A Heterobicyclic amides as CD38 inhibitors 贝林格尔·英格海姆国际有限公司 2025-02-14 CN claimed
EP-4003980-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Ribon Therapeutics Inc. (US) 2022-06-01 EP claimed
EP-4003980-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Ribon Therapeutics Inc. (US) 2022-06-01 EP disclosed